miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy
- PMID: 35976169
- DOI: 10.1515/dx-2022-0036
miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy
Abstract
Objectives: Microribonucleic acids (microRNA/miRNA/miR-) are predicted to be useful in the early diagnosis, monitoring, and treatment of diabetic nephropathy (DN). We aimed to investigate the relationship of DN to miR-21-3p, miR-29a-3p, miR-29b-3p, miR-29c-3p, miR-126-3p, miR-129-1-3p, miR-137, miR-192-5p, miR-212-3p, and miR-320c.
Methods: There were 50 healthy controls and 100 patients with type 2 diabetes mellitus (T2DM). The diabetic patients were divided into three subgroups: normal to mildly increased (A1, n=51), moderately increased (A2, n=25), and severely increased (A3, n=24) albuminuria. The biochemical measurements were analysed using Roche Cobas 8000. The plasma miRNAs were analysed using RT-qPCR based on SYBR green chemistry.
Results: The relative expression of miR-21-3p was significantly lower in the (A3 p=0.005, 6.6-fold decrease) and DN (A1 + A3) (p=0.005, 6.6-fold decrease) groups compared to the controls. The relative expression of miR-192-5p was also significantly lower in the DN group (p=0.027, 2.4-fold decrease) compared to the controls. The area under curve value was 0.726 for miR-21-3p and 0.717 for miR-192-5p for distinguishing the DN group from the controls.
Conclusions: The decreased expressions of miR-21-3p and miR-192-5p are associated with the development of DN and may be potential biomarkers for the early diagnosis of DN.
Keywords: circulating microRNAs; diabetes mellitus; diabetic nephropathy.
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
Similar articles
-
Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients.PLoS One. 2016 Mar 1;11(3):e0150154. doi: 10.1371/journal.pone.0150154. eCollection 2016. PLoS One. 2016. PMID: 26930277 Free PMC article.
-
Differential microRNA Profiles Predict Diabetic Nephropathy Progression in Taiwan.Int J Med Sci. 2016 Jun 1;13(6):457-65. doi: 10.7150/ijms.15548. eCollection 2016. Int J Med Sci. 2016. PMID: 27279796 Free PMC article.
-
Expression Profiling and Clinical Significance of Plasma MicroRNAs in Diabetic Nephropathy.J Diabetes Res. 2019 May 14;2019:5204394. doi: 10.1155/2019/5204394. eCollection 2019. J Diabetes Res. 2019. PMID: 31218232 Free PMC article.
-
Network pharmacology-based identification of miRNA expression of Astragalus membranaceus in the treatment of diabetic nephropathy.Medicine (Baltimore). 2022 Feb 4;101(5):e28747. doi: 10.1097/MD.0000000000028747. Medicine (Baltimore). 2022. PMID: 35119030 Free PMC article.
-
Identification of candidate microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies.J Nephrol. 2018 Dec;31(6):813-831. doi: 10.1007/s40620-018-0511-5. Epub 2018 Jul 17. J Nephrol. 2018. PMID: 30019103 Review.
Cited by
-
MiR-29b Alleviates High Glucose-induced Inflammation and Apoptosis in Podocytes by Down-regulating PRKAB2.Endocr Metab Immune Disord Drug Targets. 2024;24(8):981-990. doi: 10.2174/0118715303267375231204103200. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38204237 Free PMC article.
-
OL-FS13 Alleviates Cerebral Ischemia-reperfusion Injury by Inhibiting miR-21-3p Expression.Curr Neuropharmacol. 2023;21(12):2550-2562. doi: 10.2174/1570159X21666230502111013. Curr Neuropharmacol. 2023. PMID: 37132110 Free PMC article.
-
Panel miRNAs are potential diagnostic markers for chronic kidney diseases: a systematic review and meta-analysis.BMC Nephrol. 2024 Aug 13;25(1):261. doi: 10.1186/s12882-024-03702-y. BMC Nephrol. 2024. PMID: 39138396 Free PMC article.
-
Roles of microRNA-192 in diabetic nephropathy: the clinical applications and mechanisms of action.Front Endocrinol (Lausanne). 2023 Jun 15;14:1179161. doi: 10.3389/fendo.2023.1179161. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37396169 Free PMC article. Review.
-
Potential of miR-192-5p as a diagnostic marker for children with severe pneumonia and respiratory failure and its predictive value for prognosis.Cent Eur J Immunol. 2025;50(1):98-104. doi: 10.5114/ceji.2025.149249. Epub 2025 Apr 9. Cent Eur J Immunol. 2025. PMID: 40620650 Free PMC article.
References
-
- World Health Organization . Global report on diabetes . Geneva, Switzerland: World Health Organization; 2016978–88 p.
-
- KDIGO CKD Work Group . Kidney Disease: improving Global Outcomes (KDIGO) 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–136.
-
- Diabetes Canada Clinical Practice Guidelines Expert Committee . Diabetes Canada 2018 clinical practice guidelines for the prevention and management of Diabetes in Canada. Can J Diabetes 2018;42:1–342.
-
- Simpson, K, Wonnacott, A, Fraser, DJ, Bowen, T. MicroRNAs in diabetic nephropathy: from Biomarkers to therapy. Curr Diabetes Rep 2016;16:1–7. https://doi.org/10.1007/s11892-016-0724-8 . - DOI
-
- Jonas, S, Izaurralde, E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 2015;16:421–33. https://doi.org/10.1038/nrg3965 . - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical